Comparison of the effects of aprotinin and tranexamic acid on blood loss and red blood cell transfusion requirements during the late stages of liver transplantation

Transfusion

Volumn 46, Issue 4, 2006, Pages 595-605

  Ickx, Brigitte E ^a   Van Der Linden, Philippe J ^b   Melot, Christian ^b   Wijns, Walter ^b   De Pauw, Luc ^b   Vandestadt, Jean ^b   Hut, Florence ^b   Pradier, Olivier ^b  

^a ERASME HOSPITAL   (Belgium)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ANTIFIBRINOLYTIC AGENT; APROTININ; BIOLOGICAL MARKER; TRANEXAMIC ACID;

ADULT; ARTICLE; BLEEDING; BLOOD CLOTTING; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; ERYTHROCYTE TRANSFUSION; FEMALE; FIBRINOLYSIS; HUMAN; HUMAN CELL; LIVER CIRRHOSIS; LIVER GRAFT; LIVER TRANSPLANTATION; MAJOR CLINICAL STUDY; MALE; PERIOPERATIVE PERIOD; RANDOMIZED CONTROLLED TRIAL; REPERFUSION;

ADULT; APROTININ; BLOOD LOSS, SURGICAL; ERYTHROCYTE TRANSFUSION; FEMALE; FIBRINOLYSIS; HEMOSTATICS; HUMANS; INTRAOPERATIVE CARE; LIVER CIRRHOSIS; LIVER TRANSPLANTATION; MALE; MIDDLE AGED; POSTOPERATIVE HEMORRHAGE; TRANEXAMIC ACID;

EID: 33645321129     PISSN: 00411132     EISSN: 15372995     Source Type: Journal    
DOI: 10.1111/j.1537-2995.2006.00770.x     Document Type: Article

References (48)

1. Mor E Jennings L Gonwa TA et al. The impact of operative bleeding on outcome in transplantation of the liver. Surg Gynecol Obstet 1993 176 219 27.
2. Miki C Iriayama K Gunson BK et al. Influence of intraoperative blood loss on plasma levels of cytokines and endotoxin and subsequent graft function. Arch Surg 1997 132 136 41.
3. Ramos E Dalmau A Sabate A et al. Intraoperative red blood cell transfusion in liver transplantation: influence on patient outcome, prediction of requirements, and measures to reduce them. Liver Transplant 2003 9 1320 7.
4. Cacciarelli TV Keeffe EB Moore DH et al. Effect of intraoperative blood transfusion on patient outcome in hepatic liver transplantation. Arch Surg 1999 134 25 9.
5. Porte RJ Hendriks HG Slooff MJ. Blood conservation in liver transplantation. The role of aprotinin. J Cardiothorac Vasc Anesth 2004 18 4 Suppl S31 7.
6. Porte RJ Knot EA Bontempo FA. Hemostasis in liver transplantation. Gastroenterology 1989 97 488 501.
7. Ozier Y Steib A Ickx B N et al. Haemostatic disorders during liver transplantation. Eur J Anaesthesiol 2001 18 208 18.
8. Himmelreich G Jochum M Bechstein WO et al. Mediators of leukocyte activation play a role in disseminated intravascular coagulation during orthotopic liver transplantation. Transplantation 1994 57 354 8.
9. Porte RJ Molenaar IQ Begliomini B et al. Aprotinin and transfusion requirements in orthotopic liver transplantation: a multicentre randomised double-blind study. EMSALT Study Group. Lancet 2000 355 1303 9.
10. Findlay JY Rettke SR Ereth MH et al. Aprotinin reduces red blood cell transfusion in orthotopic liver transplantation: a prospective, randomized, double-blind study. Liver Transplant 2001 7 802 7.
11. Boylan JF Klinck JR Sandler AN et al. Tranexamic acid reduces blood loss, transfusion requirements, and coagulation factor use in primary liver transplantation. Anesthesiology 1996 85 1043 8.
12. Dalmau A Sabate A Acosta F et al. Tranexamic acid reduces red cell transfusion better than epsilon-aminocaproic acid or placebo in liver transplantation. Anesth Analg 2000 91 29 34.
13. Segal H Hunt BJ. Aprotinin: pharmacological reduction of perioperative bleeding. Lancet 2000 355 1289 90.
14. Kozek-Langenecker SA Mohammad SF Masaki T et al. The effects of aprotonin on platelets in vitro using whole blood flow cytometry. Anesth Analg 2000 90 12 6.
15. Levy JH Tanaka KA. Inflammatory response to cardiopulmonary bypass. Ann Thorac Surg 2003 75 S715 20.
16. Dunn CJ Goa KL. Tranexamic acid: a review of its use in surgery and other indications. Drugs 1999 57 1005 32.
17. Ogston D. Current status of antifibrinolytic drugs. Blood Rev 1989 3 1 4.
18. Astedt B. Clinical pharmacology of tranexamic acid. Scand J Gastroenterol 1987 137 22 5.
19. Renckens R Weijer S de Vos AF et al. Inhibition of plasmin activity by tranexamic acid does not influence inflammatory pathways during human endotoxemia. Arterioscler Thromb Vasc Biol 2004 24 483 8.
20. Royston D. Aprotinin versus lysine analogues: the debate continues. Ann Thorac Surg 1998 65 4 Suppl S9 28.
21. Levi M Cromheecke ME de Jonge E et al. Pharmacological strategies to decrease excessive blood loss in cardiac surgery: a meta-analysis of clinically relevant endpoints. Lancet 1999 354 1940 7.
22. Dietrich W Spath P Zuhlsdorf M et al. Anaphylactic reactions to aprotinin reexposure in cardiac surgery: relation to antiaprotinin immunoglobulin G and E antibodies. Anesthesiology 2001 95 64 71.
23. Ramsay MA Randall HB Burton EC. Intravascular thrombosis and thromboembolism during liver transplantation: antifibrinolytic therapy implicated? Liver Transplant 2004 10 310 4.
24. Fitzsimons MG Peterfreund RA Raines DE. Aprotinin administration and pulmonary thromboembolism during orthotopic liver transplantation: report of two cases. Anesth Analg 2001 92 1418 21.
25. O'Connor CJ Roozeboom D Brown R et al. Pulmonary embolism during liver transplantation: possible association with antifibrinolytic drugs and novel treatment options. Anesth Analg 2000 91 296 9.
26. Sopher M Braunfeld M Shackleton CH et al. Fatal pulmonary embolism during liver transplantation. Anesthesiology 1997 87 429 32.
27. Busque S Esquivel CO Concepcion W So SK. Experience with the piggyback technique without caval occlusion in adult orthotopic liver transplantation. Transplantation 1998 65 77 82.
28. Griffith BP Shaw BW Jr. Hardesty RL et al. Veno-venous bypass without systemic anticoagulation for transplantation of the human liver. Surg Gynecol Obstet 1985 160 270 2.
29. Despotis GJ Alsoufiev A Goodnough LT et al. Aprotinin prolongs whole blood activated partial thromboplastin time but not whole blood prothrombin time in patients undergoing cardiac surgery. Anesth Analg 1995 81 919 24.
30. Wang JS Lin CY Hung WT et al. In vitro effect of aprotinin on activated clotting time measured with different activators. J Thorac Cardiovasc Surg 1992 1045 1135 40.
31. Grosse H Lobbes W Frambach M et al. The use of high dose aprotinin in liver transplantation: the influence on fibrinolysis and blood loss. Thromb Res 1991 63 287 97.
32. Garcia L Sabate A Domenech P et al. Aprotinin in orthotopic liver transplantation. Transplant Proc 1995 27 2290 1.
33. Garcia-Huete L Domenech P Sabate A et al. The prophylactic effect of aprotinin on intraoperative bleeding in liver transplanation: a randomized clinical study. Hepatology 1997 26 1143 8.
34. Himmelreich G Muser M Neuhaus P et al. Different aprotinin applications influencing hemostatics changes in orthotopic liver transplantation. Transplantation 1992 53 132 6.
35. Espana F Estelles A Griffin JH et al. Aprotinin is a competitive inhibitor of activated protein C. Thromb Res 1989 56 751 6.
36. Sweeney JD Blair AJ Dupuis MP King TC Moulton A. Aprotinin, cardiac surgery, and factor V Leiden. Transfusion 1997 37 1173 8.
37. Gologorsky E De Wolf AM Scott V et al. Intracardiac thrombus formation and pulmonary thromboembolism immediately after graft reperfusion in 7 patients undergoing liver transplantation. Liver Transplant 2001 7 783 9.
38. Lentschener C Roche K Ozier Y. A review of aprotinin in orthotopic liver transplantation: can its harmful effects offset its beneficial effects? Anesth Analg 2005 100 1248 55.
39. Dalmau A Sabaté A Koo M et al. Prophylactic use of tranexamic acid and incidence of arterial thrombosis in liver transplantation. Anesth Analg 2001 93 516.
40. Parrilla P Sanchez-Bueno F Figueras J et al. Analysis of the complications of the piggy-back technique in 1112 liver transplants. Transplant Proc 1999 31 2388 9.
41. Kaspar M Ramsay MA Nguyen AT et al. Continuous small-dose tranexamic acid reduces fibrinolysis but not transfusion requirements during orthotopic liver transplantation. Anesth Analg 1997 85 281 5.
42. Andersson L Nilsson IM Nilehn JE et al. Experimental and clinical studies on AMCA, the antifibrinolytically active isomer of p-aminomethyl cyclohexane carboxylic acid. Scand J Haematol 1965 2 230 47.
43. Kang Y. Transfusion based on clinical coagulation monitor-ing does reduce hemorrhage during liver transplantation. Liver Transplant Surg 1997 3 655 9.
44. Dalmau A Sabate A Koo M et al. The prophylactic use of tranexamic acid and aprotinin in orthotopic liver transplantation: a comparative study. Liver Transplant 2004 10 279 84.
45. Ozier Y Pessione F Samain E Courtois F et al. French Study Group on Blood Transfusion in Liver Transplantation. Institutional variability in transfusion practice for liver transplantation. Anesth Analg 2003 97 671 9.
46. Gerlach H Grosse F Rossaint R et al. The relevance of perioperative coagulation parameters to indications for blood transfusion: a retrospective analysis of 300 liver transplantations. Anaesthetist 1994 43 168 77.
47. Reyle-Hahn M Rossaint R. Coagulation techniques are not important in directing blood product transfusion during liver transplantation. Liver Transplant Surg 1997 3 659 63.
48. Bechtel JF Prosch J Sievers HH et al. Is the kaolin or celite activated clotting time affected by the tranexamic acid Ann Thorac Surg 2002 74 390 3.